Friday June 22, 1:01 pm Eastern Time
Press Release
SOURCE: 3-Dimensional Pharmaceuticals, Inc.
3DP Receives Four Patents for New Classes of
Compounds
Protease Inhibitors Exhibiting Antithrombotic and Anticoagulant
Activity
EXTON, Pa., June 22 /PRNewswire/ -- 3-Dimensional Pharmaceuticals, Inc. (Nasdaq:
DDDP - news) today announced the issuance of four new patents (U.S. Patents No.
6,204,263, No. 6,225,302, No. 6,235,778, and No. 6,245,763) covering novel classes of
protease inhibitors, certain of which exhibit antithrombotic activity via direct, selective
inhibition of thrombin. The patents also describe compositions for inhibiting loss of blood
platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin,
inhibiting thrombus formation, inhibiting embolus formation, and other uses.
``Cardiovascular compounds are a key focus of 3DP's research efforts,'' said David C.
U'Prichard, Ph.D. ``These patents cover four novel classes of potent inhibitors of certain
proteases implicated in a number of potentially life- threatening cardiovascular conditions
affecting large populations. We are pleased with the continuing growth of 3DP's portfolio of
intellectual property related to our discovery programs.''
A team of 3DP scientists developed each of the inventions covered by the four patents.
Patent No. 6,204,263 covers Pyrazinone Protease Inhibitors, Patent No. 6,225,302, covers
Amidino Protease Inhibitors, Patent No. 6,235,778, covers Aminoguanidines and
Alkoxyguanidines as Protease Inhibitors and Patent No. 6,245,763 covers Heteroaryl
Aminoguanidines and Alkoxyguanadines and Their Use as Protease Inhibitors.
3-Dimensional Pharmaceuticals, Inc. (http://www.3dp.com) is a post-genomics drug
discovery company dedicated to revolutionizing small- molecule discovery. 3DP has
developed and integrated a set of proprietary technologies called DiscoverWorks(TM),
which accelerates and improves the drug discovery process and capitalizes on opportunities
arising from human genome sequencing. 3DP technologies can be applied to virtually any
disease target, and can produce compounds suitable for drug development in a more timely
and cost-effective manner and with a higher probability of success than conventional methods. 3DP is using its technologies
both to assist collaborators in discovering drug candidates, and to discover and develop its own drug candidates.
Statements in this press release that are not strictly historical are ``forward-looking'' statements that involve a high degree of risk
and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those
projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited
to, risks associated with our new and uncertain technologies, clinical trials and product development, the long and arduous
process of obtaining regulatory approvals, our dependence on existing strategic alliances, our dependence on patents and
proprietary rights, our ability to protect and enforce our patents and proprietary rights, the development and availability of
competitive products or technologies and our ability to attract and retain talented employees and to manage our expansion.
These risks and uncertainties are discussed in the section of the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission entitled ``Factors Affecting the Company's Prospects.''
SOURCE: 3-Dimensional Pharmaceuticals, Inc. |
